Ara-C clinical trials
Ara-C is named as an intervention in 42 current clinical trials in our Canada, Israel, Mexico, China, Australia, Germany, France, Taiwan, USA, Spain, Italy, Belgium, Poland, Czechia, Singapore, UK, Portugal, South Korea, India, Netherlands, Sweden, Switzerland, Austria, Japan and Egypt registers. 20 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (12). The most-studied condition is Acute Myeloid Leukemia.
Patient leaflets for Ara-C
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ara-C
42 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Ara-C
56 conditionsAll 56 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia | 10 |
| Acute Lymphoblastic Leukemia | 5 |
| B Acute Lymphoblastic Leukemia | 4 |
| Down Syndrome | 4 |
| Recurrent B Acute Lymphoblastic Leukemia | 3 |
| Hematopoietic Stem Cell Mobilization | 2 |
| Mixed Phenotype Acute Leukemia | 2 |
| B Lymphoblastic Lymphoma | 2 |
| Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | 2 |
| Acute Myeloid Leukemia Post Cytotoxic Therapy | 2 |
| Acute Myeloid Leukemia, Myelodysplasia-Related | 2 |
| Acute Myeloid Leukemia (AML) | 1 |
| Multiple Myeloma | 1 |
| Langerhans Cell Histiocytosis | 1 |
| Acute T Lymphpblastic Leukemia/Lymphoma | 1 |
| Relapsed/Refractory AML | 1 |
| Precursor B-Cell Lymphoblastic Leukemia | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Leukemia, Myeloid, Acute(AML) | 1 |
| Hematopoietic Stem Cell Transplantation (HSCT) | 1 |
| Leukemia | 1 |
| Leukemia, Myeloid | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Relapsed/Refractory Large B-Cell Lymphoma | 1 |
| Early T Acute Lymphoblastic Leukemia | 1 |
| T-Acute Lymphoblastic Leukemia | 1 |
| Mixed Phenotype Acute Leukemia, T/Myeloid, Nos | 1 |
| Non-Hodgkin's Lymphoma | 1 |
| Myelodysplastic Syndromes | 1 |
| Secondary Acute Myeloid Leukemia | 1 |
| Chronic Myelomonocytic Leukemia | 1 |
| T Acute Lymphoblastic Leukemia | 1 |
| B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 1 |
| Central Nervous System Leukemia | 1 |
| Myelodysplastic Syndrome | 1 |
| Myeloid Leukemia Associated With Down Syndrome | 1 |
| Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | 1 |
| Acute Lymphoblastic Leukemia, Pediatric | 1 |
| Adult T Acute Lymphoblastic Leukemia | 1 |
| Ann Arbor Stage II Adult Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage II Childhood Lymphoblastic Lymphoma | 1 |
| Ann Arbor Stage III Adult Lymphoblastic Lymphoma | 1 |
| Recurrent Acute Leukemia of Ambiguous Lineage | 1 |
| Recurrent Acute Lymphoblastic Leukemia | 1 |
| Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage | 1 |
| Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged | 1 |
| B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 |
| Core Binding Factor Acute Myeloid Leukemia | 1 |
| Childhood Cancer | 1 |
| Mature B-Cell Lymphoma | 1 |
| Acute Lymphoblastic Lymphoma | 1 |
| Recurrent B Lymphoblastic Lymphoma | 1 |
| Refractory B Acute Lymphoblastic Leukemia | 1 |
| Refractory B Lymphoblastic Lymphoma | 1 |
| Recurrent Acute Myeloid Leukemia | 1 |
| Refractory Acute Myeloid Leukemia | 1 |
Sponsors
lead sponsor per trial+ 4 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Ara-C trials
How many clinical trials are testing Ara-C?
42 current trials in our Canada, Israel, Mexico, China, Australia, Germany, France, Taiwan, USA, Spain, Italy, Belgium, Poland, Czechia, Singapore, UK, Portugal, South Korea, India, Netherlands, Sweden, Switzerland, Austria, Japan and Egypt registers name Ara-C (also registered as COP, COPD M3, CYM) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Ara-C trials recruiting patients?
Yes. 20 of the 42 trials are recruiting: 8 with sites in Canada, 5 with sites in Israel, 8 with sites in Mexico, 10 with sites in China, 5 with sites in Australia, 2 with sites in Germany, 1 with sites in France, 1 with sites in Taiwan, 1 with sites in USA, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in UK, 1 with sites in Portugal and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ara-C clinical trials?
National Cancer Institute (NCI) (12), Children's Oncology Group (7), St. Jude Children's Research Hospital (3) and The Affiliated People's Hospital of Ningbo University (2), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ara-C works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ara-C works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ara-C (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.